Enliven Therapeutics, Inc. Segments Disclosure
13. Segment Information
Segment financial information used by the CODM to assess segment performance and make decisions about resource allocation was as follows (in thousands):
|
|
Year Ended December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Research and development: |
|
|
|
|
|
|
||
External expenses |
|
|
|
|
|
|
||
ELVN-001 |
|
$ |
23,162 |
|
|
$ |
15,402 |
|
ELVN-002 |
|
|
15,713 |
|
|
|
28,488 |
|
Other (1) |
|
|
12,403 |
|
|
|
10,534 |
|
Internal expenses |
|
|
|
|
|
|
||
Salaries and benefits |
|
|
17,432 |
|
|
|
13,838 |
|
Stock-based compensation |
|
|
14,332 |
|
|
|
10,044 |
|
Facilities, laboratory supplies and other (2) |
|
|
2,814 |
|
|
|
2,472 |
|
Total research and development expenses |
|
|
85,856 |
|
|
|
80,778 |
|
General and administrative: |
|
|
|
|
|
|
||
Salaries and benefits |
|
|
5,158 |
|
|
|
5,207 |
|
Stock-based compensation |
|
|
19,687 |
|
|
|
10,130 |
|
Other (3) |
|
|
8,957 |
|
|
|
8,439 |
|
Total general and administrative expenses |
|
|
33,802 |
|
|
|
23,776 |
|
Total operating expenses |
|
|
119,658 |
|
|
|
104,554 |
|
Other income (expense), net |
|
|
15,964 |
|
|
|
15,530 |
|
Net loss |
|
$ |
(103,694 |
) |
|
$ |
(89,024 |
) |
(1) Other external research and development costs primarily represent contract research, preclinical studies and manufacturing costs that are not related to ELVN-001 and ELVN-002, as well as general consulting costs.
(2) Other internal research and development costs primarily represent travel, expensed software and depreciation.
(3) Other general and administrative costs primarily represent insurance, professional fees, expensed software, taxes and travel.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 3, 2026 | Showing above |
| 2024 | Mar 13, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.